185 related articles for article (PubMed ID: 37958497)
1. Neuroblastoma Patients' Outcome and Chromosomal Instability.
Ognibene M; De Marco P; Amoroso L; Fragola M; Zara F; Parodi S; Pezzolo A
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958497
[TBL] [Abstract][Full Text] [Related]
2. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.
Villamón E; Piqueras M; Mackintosh C; Alonso J; de Alava E; Navarro S; Noguera R
Virchows Arch; 2008 Jul; 453(1):47-55. PubMed ID: 18574593
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
[TBL] [Abstract][Full Text] [Related]
7. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
8. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
9. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.
Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X
Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736
[TBL] [Abstract][Full Text] [Related]
10. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
[TBL] [Abstract][Full Text] [Related]
11. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G; Michon J; Ribeiro A; Pierron G; Mosseri V; Rubie H; Munzer C; Bénard J; Auger N; Combaret V; Janoueix-Lerosey I; Pearson A; Tweddle DA; Bown N; Gerrard M; Wheeler K; Noguera R; Villamon E; Cañete A; Castel V; Marques B; de Lacerda A; Tonini GP; Mazzocco K; Defferrari R; de Bernardi B; di Cataldo A; van Roy N; Brichard B; Ladenstein R; Ambros I; Ambros P; Beiske K; Delattre O; Couturier J
Br J Cancer; 2011 Dec; 105(12):1940-8. PubMed ID: 22146831
[TBL] [Abstract][Full Text] [Related]
12. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
13. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
[TBL] [Abstract][Full Text] [Related]
14. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
15. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours.
Fusco P; Parisatto B; Rampazzo E; Persano L; Frasson C; Di Meglio A; Leslz A; Santoro L; Cafferata B; Zin A; Cimetta E; Basso G; Esposito MR; Tonini GP
BMC Cancer; 2019 Oct; 19(1):970. PubMed ID: 31638925
[TBL] [Abstract][Full Text] [Related]
17. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
18. Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.
Fernández-Blanco B; Berbegall AP; Martin-Vañó S; Castel V; Navarro S; Noguera R
Neoplasia; 2021 Jan; 23(1):12-20. PubMed ID: 33190090
[TBL] [Abstract][Full Text] [Related]
19. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
20. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
Stallings RL; Nair P; Maris JM; Catchpoole D; McDermott M; O'Meara A; Breatnach F
Cancer Res; 2006 Apr; 66(7):3673-80. PubMed ID: 16585193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
